Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer
- 30 September 2009
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 28 (2) , 186-194
Abstract
Purpose: To determine in patients, with locally advanced or metastatic pancreatic cancer (APC), efficacy and safety of treatment with intravenous paclitaxel loaded polymeric micelle (GPM). Patients and methods: This was a multicenter, open-label Phase II study. Patients with APC, ECOG performance status ≤ 2, no prior chemotherapy and adequate organ function were treated with 3-hour GPM infusions every 3 weeks. Initial patients were treated with 435 mg/m2 (n = 11). The dose was reduced for subsequent patients to 350 or 300 mg/m2 (n = 45). Primary endpoint was time to tumor progression (TTP). Results: 56 patients were enrolled. Median TTP for patients treated with 300 or 350 mg/m2 doses was 3.2 months (95% CI, 2.6–4.2). Median progression free survival (PFS) was 2.8 months (95% CI, 1.4–4.0). Median overall survival (OS) was 6.5 months (95% CI, 5.1–7.9). Among patients treated with above doses of GPM, there was 1 complete remission (CR) and 2 partial remissions (PR) with an overall response rate (ORR) of 6.7%. Disease control rate (CR + PR + stable disease) was 60.0%. Most common grade 3 toxicities were: neutropenia (40.0%), fatigue (17.8%), infection, dehydration, neuropathy (each 13.3%), and abdominal pain (11.1%). Conclusions: Treatment of APC with GPM at a dose of 300 mg/m2 q 3 weeks was well tolerated and common toxicities were qualitatively similar to Cremophor-based paclitaxel. GPM monotherapy resulted in OS and other efficacy parameters preferable to that seen historically with gemcitabine. Future studies of GPM in combination with other agents for treatment of APC are warranted.Keywords
This publication has 26 references indexed in Scilit:
- Pancreatic cancer: from molecular pathogenesis to targeted therapyCancer and Metastasis Reviews, 2008
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinomaAnti-Cancer Drugs, 2000
- A phase II studyEuropean Journal of Cancer, 2000
- Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II StudyJournal of Clinical Oncology, 1999
- Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative studyBritish Journal of Cancer, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.Journal of Clinical Oncology, 1997
- Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinomaEuropean Journal of Cancer, 1996
- Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activityJournal of Medicinal Chemistry, 1992